文献速递肿瘤 PET/CT

PET/MR在疑似隐匿性肿瘤中优于PET/CT

PET/MR Outperforms PET/CT in Suspected Occult Tumors.
PubMed 文献 · Clin Nucl Med · 2017-01-01

这项前瞻性研究对43例疑似隐匿性原发肿瘤患者序贯行PET/CT与PET/MR检查,参照标准显示14例找到原发灶、16例原发灶仍隐匿、13例病灶为良性。PET/MR对原发肿瘤检出的灵敏度/特异度为0.85/0.97,优于PET/CT的0.69/0.73(P=0.020);对淋巴结转移和远处转移的检出与PET/CT相当。

要点

  • PET/MR对原发肿瘤检出的灵敏度/特异度为0.85/0.97,优于PET/CT的0.69/0.73(P=0.020)。
  • 淋巴结转移检出两组灵敏度/特异度分别为0.93/1.00与0.93/0.93(P=0.157),无显著差异。
  • PET/CT较PET/MR更易将生理性FDG摄取误判为恶性(8例 vs 1例)。

核心结论

  • PET/MR在疑似隐匿性恶性肿瘤的检查中优于PET/CT。
  • 作者认为PET/MR可能替代PET/CT以改善临床工作流程。

研究设计与样本

  • 前瞻性研究,经机构审查委员会批准,连续对43例(男性22例;中位年龄58岁,范围20-86岁)疑似隐匿性原发肿瘤患者序贯行PET/CT-MR检查。
  • 分别评估PET/CT与PET/MR对原发肿瘤、淋巴结转移和远处转移的检出,采用Wilcoxon符号秩检验比较两者诊断准确性。

主要发现

  • 参照标准显示,14例患者找到原发病灶,16例原发病灶仍隐匿,其余13例病灶证实为良性。
  • 原发肿瘤检出:PET/MR灵敏度/特异度0.85/0.97,PET/CT为0.69/0.73,PET/MR优于PET/CT(P=0.020)。
  • 淋巴结转移检出:PET/MR灵敏度/特异度0.93/1.00,PET/CT为0.93/0.93,两者相当(P=0.157)。
  • 远处转移检出:PET/MR灵敏度/特异度1.00/0.97,PET/CT为0.82/1.00,两者相当(P=0.564)。
  • PET/CT较PET/MR更易将生理性FDG摄取误判为恶性(8例 vs 1例)。

临床怎么用

  • 作者认为PET/MR可能替代PET/CT以改善临床工作流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To compare the diagnostic accuracy of PET/MR and PET/CT in patients with suspected occult primary tumors. METHODS: This prospective study was approved by the institutional review board. Sequential PET/CT-MR was performed in 43 patients (22 male subjects; median age, 58 years; range, 20-86 years) referred for suspected occult primary tumors. Patients were assessed with PET/CT and PET/MR for the presence of a primary tumor, lymph node metastases, and distant metastases. Wilcoxon signed-rank test was performed to compare the diagnostic accuracy of PET/CT and PET/MR. RESULT: According to the standard of reference, a primary lesion was found in 14 patients. In 16 patients, the primary lesion remained occult. In the remaining 13 patients, lesions proved to be benign. PET/MR was superior to PET/CT for primary tumor detection (sensitivity/specificity, 0.85/0.97 vs 0.69/0.73; P = 0.020) and comparable to PET/CT for the detection of lymph node metastases (sensitivity/specificity, 0.93/1.00 vs 0.93/0.93; P = 0.157) and distant metastases (sensitivity/specificity, 1.00/0.97 vs 0.82/1.00; P = 0.564). PET/CT tended to misclassify physiologic FDG uptake as malignancy compared with PET/MR (8 patients vs 1 patient). CONCLUSIONS: PET/MR outperforms PET/CT in the workup of suspected occult malignancies. PET/MR may replace PET/CT to improve clinical workflow.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Sekine T, Barbosa FG, Sah BR, et al. PET/MR Outperforms PET/CT in Suspected Occult Tumors. Clin Nucl Med. 2017. PMID: 27922861. doi:10.1097/RLU.0000000000001461

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。